CZ2001126A3 - Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí - Google Patents

Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí Download PDF

Info

Publication number
CZ2001126A3
CZ2001126A3 CZ2001126A CZ2001126A CZ2001126A3 CZ 2001126 A3 CZ2001126 A3 CZ 2001126A3 CZ 2001126 A CZ2001126 A CZ 2001126A CZ 2001126 A CZ2001126 A CZ 2001126A CZ 2001126 A3 CZ2001126 A3 CZ 2001126A3
Authority
CZ
Czechia
Prior art keywords
acid
phenyl
methyl
biphenyl
hydroxy
Prior art date
Application number
CZ2001126A
Other languages
Czech (cs)
English (en)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of CZ2001126A3 publication Critical patent/CZ2001126A3/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
CZ2001126A 1998-07-21 1999-06-18 Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí CZ2001126A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
CZ2001126A3 true CZ2001126A3 (cs) 2002-01-16

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2001126A CZ2001126A3 (cs) 1998-07-21 1999-06-18 Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí

Country Status (25)

Country Link
EP (1) EP1098662A2 (is)
JP (1) JP2002521328A (is)
KR (1) KR20010083134A (is)
CN (1) CN1310629A (is)
AP (1) AP2001002035A0 (is)
AU (1) AU4701799A (is)
BG (1) BG105162A (is)
BR (1) BR9912296A (is)
CA (1) CA2335062A1 (is)
CZ (1) CZ2001126A3 (is)
EA (1) EA200100153A1 (is)
EE (1) EE200100046A (is)
HR (1) HRP20010055A2 (is)
HU (1) HUP0102880A3 (is)
ID (1) ID30030A (is)
IL (1) IL140982A0 (is)
IS (1) IS5809A (is)
NO (1) NO20010291D0 (is)
OA (1) OA11584A (is)
PL (1) PL346011A1 (is)
SK (1) SK502001A3 (is)
TR (1) TR200100205T2 (is)
WO (1) WO2000004892A2 (is)
YU (1) YU3501A (is)
ZA (1) ZA200100294B (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149145A0 (en) * 1999-11-05 2002-11-10 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
CA2393825A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
EP1314423A4 (en) * 2000-09-01 2004-05-19 Sankyo Co MEDICAL CONNECTIONS
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
ATE399012T1 (de) * 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
EP1539744A4 (en) * 2002-07-11 2007-06-06 Vicuron Pharm Inc N-HYDROXYAMIDE DERIVATIVES WITH ANTIBACTERIAL EFFECT
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1997005868A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
JP2000511175A (ja) * 1996-05-17 2000-08-29 ワーナー―ランバート・コンパニー ビフェニルスルホンアミドマトリックスメタロプロテイナーゼ阻害剤
CA2256716A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
IS5809A (is) 2001-01-12
BG105162A (en) 2001-12-29
BR9912296A (pt) 2001-04-17
HUP0102880A3 (en) 2002-11-28
KR20010083134A (ko) 2001-08-31
JP2002521328A (ja) 2002-07-16
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
CN1310629A (zh) 2001-08-29
HRP20010055A2 (en) 2002-04-30
EE200100046A (et) 2002-06-17
PL346011A1 (en) 2002-01-14
ZA200100294B (en) 2002-01-10
YU3501A (sh) 2005-06-10
WO2000004892A2 (en) 2000-02-03
SK502001A3 (en) 2002-06-04
WO2000004892A3 (en) 2000-05-18
HUP0102880A2 (en) 2002-06-29
NO20010291L (no) 2001-01-18
TR200100205T2 (tr) 2001-05-21
ID30030A (id) 2001-11-01
IL140982A0 (en) 2002-02-10
AU4701799A (en) 2000-02-14
EA200100153A1 (ru) 2001-08-27
NO20010291D0 (no) 2001-01-18
EP1098662A2 (en) 2001-05-16
AP2001002035A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
US6133304A (en) ACE inhibitor-MMP inhibitor combinations
KR20000057444A (ko) 심기능부전 및 심실확장의 치료 및 예방 방법
US6340709B1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
CZ2001126A3 (cs) Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí
US20020049237A1 (en) Statin-MMP inhibitor combinations
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
US20050020607A1 (en) Statin-MMP inhibitor combinations
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
AU2003248291A1 (en) Statin-matrix metalloproteinase inhibitor combinations
MXPA00005034A (en) Statin-matrix metalloproteinase inhibitor combinations